Anavex Expanding Boundaries
        in Drug Discovery
HOME  |  ABOUT US  |  PIPELINE  |  R & D  |  PUBLICATIONS  |  PARTNERING  |  INVESTORS  |  CAREERS  |  CONTACT

Publications
- Anavex
- Relevant scientific publications
 
Publications

"A novel multipotent sigma 1/M1 muscarinic activator for a comprehensive therapeutic strategy in Alzheimer’s disease"
International Geneva/Springfield Symposium on Advances in Alzheimer Therapy (2014), Geneva, Switzerland
A. Fisher, R. Medeiros, N. Bar-Ner, N. Natan, R. Brandeis, H. Elkon, V. Nahum, G. Grigoryan, M. Segal and F. Laferla
View Abstract

"The Anticipated Clinical Effect of the new Alzheimer drug ANAVEX 2-73 in a Calibrated Quantitative Systems Pharmacology Platform."
CNS Summit 2013, Boca Raton, FL
Christopher Missling, Tangui Maurice, Athan Spiros, Patrick Roberts and Hugo Geerts.
View Poster

"Chronic treatment with the tetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic cholinergic and sigma-1 ligand, alleviates pathology in Tg2576 mice, a transgenic Alzheimer's disease model."
Society for Neuroscience 2013 Annual Meeting, San Diego, CA
Valentine Lahmy, Vanessa Villard and Tangui Maurice.
View Paper

"Blockade of Tau Hyperphosphorylation and Ab1–42 Generation by the Aminotetrahydrofuran Derivative ANAVEX2-73, a Mixed Muscarinic and r1 Receptor Agonist, in a Nontransgenic Mouse Model of Alzheimer’s Disease."
Neuropsychopharmacology (2013); 38:1706-1723.
Valentine Lahmy, Johann Meunier, Susanna Malmstro, Gaelle Naert, Laurent Givalois, Seung Hyun Kim, Vanessa Villard, Alexandre Vamvakides and Tangui Maurice.
View Paper

"Mitochondrial protection in mouse hippocampus against AΒ25-35 toxicity is induced by the novel tetrahydrofuran derivative ANAVEX2-73, a mixed σ1 receptor and cholinergic agonist.”
International Conference on Alzheimer’s and Parkinson’s Diseases 2013, March 6-10, 2013, Florence, Italy.
Valentine Lahmy, Romain Long, Didier Morin, Vanessa Villard, Alexandre Vamvakides and Tangui Maurice.
View Poster

"Mitochondrial protection is induced by the novel tetrahydrofuran derivative ANAVEX2-73 after ICV injection of oligomeric AΒ25-35 peptide in mice, a nontransgenic Alzheimer's disease model.” Neuroscience 2012, October 13-17, 2012, New Orleans, USA.
Valentine Lahmy, Romain Long, Didier Morin, Vanessa Villard, Alexandre Vamvakides and Tangui Maurice.
View Poster

"Neuroprotective efficacy of ANAVEX 2-73, a novel tetrahydrofuran derivative targeting the sigma-1 chaperone protein, in a mouse model of Alzheimer's disease: Analyses of administration schedules and combination studies with donepezil and memantine.” .
Alzheimer’s Association International Conference, July 14-19, 2012, Vancouver, BC, Canada

"New Adamantane Derivatives with Sigma Affinity and Antiproliferative Activity”. Medicinal Chemistry 8 (2012) 569-586
Stefanos Riganas, Ioannis Papanastasiou et al.
View Paper

“Synthesis, σ1, σ2-receptors binding affinity and antiproliferative action of new C1-substituted adamantanes”. Bioorganic & Medicinal Chemistry 20 (2012) 3323–3331
Stefanos Riganas, Ioannis Papanastasiou et al.
View Paper

“Preclinical development of new tetrahydrofuran derivatives targeting the sigma-1 chaperone protein as neuroprotectants in Alzheimer’s disease”. Alzheimer’s Association International Conference, July 16-21, 2011, Paris, France
Tangui Maurice, Vanessa Villard, Johann Meunier, Valentine Lahmy, Emeline Keller and Alexandre Vamvakides
View Poster

“The novel tetrahydrofuran derivative ANAVEX2-73 attenuated GSK-3β activation and Tau hyperphosphorylation in a nontransgenic Alzheimer’s disease model in mice”. Alzheimer’s Association International Conference, July 16-21, 2011, Paris, France
Valentine Lahmy, Susanna Malmstrom, Johann Meunier, Vanessa Villard, Alexandre Vamvakides and Tangui Maurice
View Poster

“The sigma-1 receptor chaperone as an inter-organelle signaling modulator”. Trends Pharmacol Sci. 2010 Sep 23.
Su TP, Hayashi T, Maurice T, Buch S, Ruoho AE.
View Paper

“Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigma 1 ({sigma}1) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative”. J Psychopharmacol (2010 Sep 9).
Villard V, Espallergues J, Keller E, Vamvakides A, Maurice T.
pubmedView abstract in PubMed
View Paper

“Antiamnesic and neuroprotective effects of the aminotetrahydrofuran derivative ANAVEX1-41 against amyloid beta(25-35)-induced toxicity in mice”. Neuropsychopharmacology (2009 May); 34(6):1552-66.
Villard V, Espallergues J, Keller E, Alkam T, Nitta A, Yamada K, Nabeshima T, Vamvakides A, Maurice T.
View Paper

“The pharmacology of sigma-1 receptors”. Pharmacology & Therapeutics (2009), journal homepage.
Tangui Maurice, Tsung-Ping Su
View Paper

“Anti-amnesic and neuroprotective activities of ANAVEX2-73, a new aminotetrahydrofuran derivative acting as a mixed muscarinic/sigma-1 ligand, in pharmacological and pathological models of amnesia”. Poster presentation in The Alzheimer’s Association 2009 International Conference on Alzheimer’s Disease (ICAD), July 11-16 in Vienna, Austria.
Vanessa Villard, Julie Espallergues, Alexandre Vamvakides and Tangui Maurice
View Abstract

“Antiamnesic and Neuroprotective Effects of the Aminotetrahydrofuran Derivative ANAVEX1-41 Against Amyloid beta25-35-Induced Toxicity in Mice”. Publication in Neuropsychopharmacology (December 2008).
Villard V, Espallergues J, Keller E, Alkam T, Nitta A, Yamada K, Nabeshima T, Vamvakides A, Maurice T
View Paper

“The neuroprotective action of ligands acting at the sigma-1 chaperone protein involves regulation of the expression of IP3 receptor subtypes and SerCa pumps”. Poster presentation in Neuroscience 2008, Nov. 15-19 in Washington, DC.
Vanessa Villard, Fanny Malhaire-Ferreux, François Monnet, Alexandre Vamvakides, Tangui Maurice
View Poster

“Neuroprotective effects of activators/agonists of the sigma-1 chaperone protein against amyloid toxicity in a mouse model”. ICAD (International conference on Alzheimer’s Disease) (26-31 July 2008), Chicago, USA
Tangui Maurice, Vanessa Villard, Johann Meunier, Emeline Keller, Fanny Malhaire, Alexandre Vamvakides
View Poster

“Neuroprotective activity of ANAVEX 1-41, an aminotetrahydrofuran derivative acting as a mixed muscarinic/sigma-1 ligands, against amyloid beta(25-35) peptide toxicity in mice”. Poster presentation in Neuroscience 2007, Nov. 3-7 in San Diego, Calif.
Vanessa Villard, Johann Meunier, Alexandre Vamvakides, Tangui Maurice
View Poster

“Anti-amnesic and neuroprotective activities of ANAVEX 2-73, a new aminotetrahydrofuran derivative acting as a mixed muscarinic/sigma-1 ligands, in pharmacological and pathological models of amnesia”. Poster presentation in Neuroscience 2007, Nov. 3-7 in San Diego, Calif.
Johann Meunier, Vanessa Villard, Julie Espallergues, Alexandre Vamvakides and Tangui Maurice
View Poster

“Anavex 7-1037, a novel small synthetic sigma ligand, induces apoptosis in human HCT116 colon cancer cells in vitro and suppression of HCT116 tumor growth in SCID mice.” Poster Presentation in the 15th Euroconference on Apoptosis & 4th Training course on ’Concepts and Methods in Programmed Cell Death’, October 26-31, 2007 in Portoroz, Slovenia.
Mahaira G Louisa, Humaira Khan, Chrisiida Tsiblouli, Pantazis Panayotis, Karamitopoulou Evangelia, Vamvakides Alexandros, and Dimas Konstantinos
View Poster

“Involvement of the sigma1 (s1) receptor in the antiamnesic, but not antidepressant-like, effects of the aminotetrahydrofuran derivative ANAVEX 1-41”. British Journal of Pharmacology (2007).
Espallergues J., Lapalud P., Christopoulos A., Avlani V.A., Sexton P.M., Vamvakides A. and Maurice T.
View Paper

“Anti-amnesic and neuroprotective potentials of aminotetrahydrofuran derivatives, mixed muscarinic/sigma1 (s1) ligands, against amyloid beta25-35 peptide toxicity in mice”. Poster Presentation in the 8e Colloque de la Société des Neurosciences (May 22-25, 2007), Montpellier, France.
Vanessa Villard, Julie Espallergues, Alexandre Vamvakides & Tangui Maurice
View Poster

“Involvement of the sigma1 (s1) receptor in the anti-amnesic effects of the aminotetrahydrofuran derivative AE14”. Poster Presentation in Neuroscience 2006, October 14-18, Atlanta, USA.
Julie Espallergues, Priscilla Lapalud, Alexandre Vamvakides, and Tangui Maurice
View Poster

“Action mechanism of anticonvulsant and anti-immobility (forced swim) effects of 3’, 4’-dihydro-N, N-dimethylspiro-[9H-fluorene-9, 2’ (5’H) furane]-3’-methanamine (AE37F)”. Ann Pharm Fr.; 62(1):49-55 (French) (2004).
Vamvakides A, Antoniou K, Daifoti Z.
pubmed View abstract in PubMed
View Publication

“Selective M1 muscarinic agonists: failure of therapeutic strategy against Alzheimer’s disease or inappropriate tactics?”. Ann Pharm Fr.; 61(3):207-10 Review (French) (2003).
Vamvakides A.
pubmedView abstract in PubMed

“Mechanism of action of tetrahydro-N, N-dimethyl-5, 5-diphenyl-3-furanemethanamine, a putative nootropic, anti-epileptic and antidepressant compound”. Ann Pharm Fr.; 60(6):415-22. (French) (2002).
Vamvakides A.
pubmedView abstract in PubMed
View Publication

“Anticonvulsant and forced swim anti-immobility effects of tetrahydro-N, N-dimethyl-2,2-diphenyl-3-furanemethanamine (AE37): common action mechanism?” Ann Pharm Fr.; 60(2):88-92. Review (French) (2002).
Vamvakides A.
pubmedView abstract in PubMed

© 2007-2014 Anavex Life Sciences Corp. - All Rights Reserved.